inj

Bitcoin opened the door, $ETH widened it for $SOL and proved that institutional demand could extend beyond the two largest cryptocurrencies.
Now Wall Street appears to be looking even deeper into the altcoin market.
Recent regulatory filings involving assets such as NEAR and Injective suggest that the next phase of crypto ETFs may already be taking shape. But investors should understand one crucial distinction:
An ETF filing is not an approval and an approval does not guarantee a price rally.
Why the ETF landscape has changed
In September 2025, the US Securities and Exchange Commission approved generic listing standards for certain commodity-based exchange-traded products.
In simple terms, qualifying crypto products can potentially reach the market through a more standardized process instead of requiring a completely separate exchange-rule battle every time.
That helped create a much wider pipeline of crypto investment products.
The market has since moved beyond Bitcoin and Ethereum, with funds offering exposure to assets including XRP, Solana, Chainlink, Avalanche and Hyperliquid.
The next question is no longer whether another altcoin can receive an ETF.
It is: Which altcoin has the liquidity, custody infrastructure and investor demand to support one successfully?
NEAR enters the conversation
An amended filing for the proposed Bitwise NEAR ETF identifies the anticipated ticker as NRR and states that the product would seek direct exposure to $NEAR Interestingly, the filing also describes earning additional NEAR through staking as a secondary objective.
That matters because staking could help an ETF generate network rewards, but it also introduces additional operational, tax and regulatory complexity.
For investors, a NEAR ETF could provide regulated exposure without requiring them to manage wallets, private keys or staking directly.
However, the filing alone does not mean the fund has received final approval or is available for trading.
Injective joins the ETF pipeline
A recently amended registration statement for the proposed 21Shares Injective ETF says its shares are expected to trade on Nasdaq.
Injective is designed around decentralized financial markets, making its appearance in an ETF filing especially interesting. It suggests issuers are beginning to explore assets based on more specialized investment narratives—not merely the largest cryptocurrencies by market capitalization.
If products linked to assets such as INJ can attract sufficient demand, Wall Street’s crypto offering could eventually begin to resemble a collection of sectors:
Store of valueSmart-contract platformsDecentralized financeBlockchain infrastructureTokenized real-world assetsDecentralized trading networks
What an ETF can—and cannot—do for an altcoin
An ETF can potentially improve accessibility, visibility and institutional participation.
It can allow investors to gain exposure through familiar brokerage and retirement accounts. It may also encourage better custody, pricing and market infrastructure.
But an ETF cannot manufacture lasting demand.
Some crypto ETFs attract meaningful capital, while others struggle with low trading volume and limited assets under management. If inflows are weak, the effect on the underlying token may be modest.
Investors should therefore look beyond the announcement and examine:
Is it only an initial filing, or has the registration become effective?Will the product hold the token directly or use derivatives?Does it include staking?What management fee will investors pay?How much money actually enters after launch?Is the underlying token sufficiently liquid?
These details matter far more than a viral headline claiming that an ETF has been “approved.”
Could ETFs trigger an altseason?
Possibly, but not necessarily the broad altseason many investors expect.
ETF capital may concentrate in a relatively small group of institutionally acceptable assets. Tokens with regulated custody, reliable pricing benchmarks, strong liquidity and established use cases could benefit disproportionately.
This may produce an institutional altcoin season rather than a market-wide surge in every smaller cryptocurrency.
That distinction could become increasingly important.
The bigger picture
The next generation of altcoin ETFs represents more than a collection of new trading products. It signals that traditional finance is beginning to classify blockchain networks according to their different functions and investment cases.
NEAR and Injective may be among the latest names entering the conversation, but they are unlikely to be the last.
The smartest approach is to monitor confirmed filings, product structures and real fund flows rather than buying solely because “ETF” appears in a headline.
Which cryptocurrency should receive the next spot ETF and would you invest through an ETF orcontinue holding the token directly? Share your view below.
This article is for educational purposes only and does not constitute financial advice. Cryptocurrency and crypto-linked investment products carry substantial risk.
#CryptoETF #NEAR #injective #INJ